Radiopharmaceutical for diagnosis of HER2-positive breast cancer with Trastuzumab- 99m -Tc
Carregando...
Data
Data de publicação
2023
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
É parte de
REUNIAO ANUAL DA FESBE, 37.; CONGRESSO ANUAL DA SBFIS, 58.; REUNIAO ANUAL DA SBNEC, 46.; REUNIAO ANUAL DA BRAVO, 21.; CONGRESSO DA SBBN, 14.; CONGRESSO DOHAD BRASIL, 2.
Exportar
Resumo
Introdução:
Trastuzumab IgG1 binds to the HER2 receptor on cancer cells, inhibiting the
growth signal and stimulating the immune system to combat them. Its use in therapy
has been employed for HER2-positive breast cancer. Advances in nuclear medicine
have enabled the development of radiopharmaceuticals for its diagnosis, consisting of
a radionuclide, a molecule that binds to the specific target, and a marker that allows
visualization of cancer cells through μPET/SPECT/CT. The 99m -Tc isotope is used in
nuclear medicine due to its suitable half-life for obtaining images, low concentrations of
the isotope, and short half-life. Trastuzumab therapy has shown efficacy in HER2+
tumors, while radiopharmaceuticals play an important role in breast cancer screening.
Objetivos:
The objective is to obtain a specific radiopharmaceutical for the HER2-positive
receptor capable of diagnosing breast tumors with high sensitivity and specificity.
Métodos:
The methodology involves the preparation of the Trastuzumab antibody
conjugated to the radioactive isotope 99m -Tc, conjugated with HYNIC-NHS and DMSO
under 60 minutes of agitation. It is then purified with C?H?NO?, followed by the addition
of 0.1 mg of Sn 2 Cl in 5μL of HCl, 1 mg of C 6 H 13 NO 5 , and 1 mg of C 2 H 4 (NHCH 2 CO2H)2
in
100 μL of C?H?NO?, and 8mCi of 99m -Tc. After incubation, the sample is washed with
PBS, and the product yield is confirmed by CCD. The stability test was performed to
observe the influence of external factors. Trastuzumab- 99m -Tc was added to mouse
saline and plasma at 37ºC and analyzed at 15 minutes, 1, 2, 3, 4, 5, 6, and 24 hours
using CCD on the Y counter.
The experiments were conducted in accordance with the approved local ethics
committee (CEUA: nº30/22). Eight-week-old female Balb/c nude mice were
subcutaneously inoculated with 1X106 SKBR3 cells (ATTC: HTB30- Positive for HER2) and 1x106
MDA-MB-231 ATTC: HTB-26 - Negative for HER2). The radiolabeling using Trastuzumab, HYNIC,
and 99m -Tc showed aradiochemical purity of ? 95%.
Resultados:
The radiolabeling using Trastuzumab, HYNIC, and 99m -Tc showed a
radiochemical purity of ? 95%. The stability study conducted in saline and plasma
demonstrated that Trastuzumab- 99m -Tc is stable for up to 24 hours with a radiochemical
purity of ? 95%.
Conclusão:
In conclusion, it has been determined that the radiolabeling of Trastuzumab-99m-Tc is feasible and
stable for up to 24 hours. The next step is the study of cellular internalization and in vitro
immunoreactivity, followed by biodistribution in animals with HER2-positive tumors when they reach
a size of 0.3 cm3, using Trastuzumab-99m-Tc.
Como referenciar
SOUZA, F.V.; SILVA, F.F.A.; ARAUJO, P.H.S.; BERNARDES, E.S. Radiopharmaceutical for diagnosis of HER2-positive breast cancer with Trastuzumab- 99m -Tc. In: REUNIAO ANUAL DA FESBE, 37.; CONGRESSO ANUAL DA SBFIS, 58.; REUNIAO ANUAL DA SBNEC, 46.; REUNIAO ANUAL DA BRAVO, 21.; CONGRESSO DA SBBN, 14.; CONGRESSO DOHAD BRASIL, 2., 27-30 de agosto, 2023, Búzios, RJ. ProceResumo expandidoedings... Campinas, SP: Galoá, 2023. Disponível em: https://repositorio.ipen.br/handle/123456789/48161. Acesso em: 20 Mar 2026.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.